SOURCE: Emerging World Pharma Inc.

November 12, 2010 12:00 ET

Emerging World Pharma Inc. President Provides Update on Sunyani, Ghana Generic Drug Manufacturing Facility

MANASSAS, VA--(Marketwire - November 12, 2010) - Emerging World Pharma Inc. (PINKSHEETS: EWPI) -- company president Brandon Keks, currently on location in Sunyani, Ghana reports that the company's strategic partner African Global Pharma (AGP) will begin the trial production test runs at its manufacturing facility next week. The generic drug manufacturing facility recently received inspection approvals by both the Food and Drug Board of Ghana (FDB) and the Ghana Standards Board (GSB). The manufacturing process will go through several phases of testing to ensure that the highest level of quality and approval standards is met. "I am extremely impressed with this manufacturing facility and its highly competent team of chemist, pharmacists and operators. I believe we should be on schedule to be in full production by the January 2011 target date," stated Emerging World Pharma president, Brandon Keks. Mr. Keks noted that while in Ghana he will be meeting with the Catholic Diocese of Sunyani, Ghana, our partners in the Diocesean Health Service Pharmacy Ltd who are our exclusive marketers to larger distribution networks. In addition, meetings are scheduled with a large association representing over 180 hospitals. The company confirms that initial production of medicines will commence in December with full production and availability expected to be ready in January.

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact Information

  • Contact:
    Joel Everret
    Emerging World Pharma Inc.
    Investor Relations Division